WO2004099824A2 - Methodes et dispositifs permettant de mesurer une substance a analyser de façon non invasive - Google Patents
Methodes et dispositifs permettant de mesurer une substance a analyser de façon non invasive Download PDFInfo
- Publication number
- WO2004099824A2 WO2004099824A2 PCT/US2004/012893 US2004012893W WO2004099824A2 WO 2004099824 A2 WO2004099824 A2 WO 2004099824A2 US 2004012893 W US2004012893 W US 2004012893W WO 2004099824 A2 WO2004099824 A2 WO 2004099824A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mid
- instrument
- infrared radiation
- radiation
- subject
- Prior art date
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 77
- 238000005259 measurement Methods 0.000 title description 45
- 230000005855 radiation Effects 0.000 claims abstract description 216
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 239000008103 glucose Substances 0.000 claims description 129
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 108
- 210000001508 eye Anatomy 0.000 claims description 44
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- 239000000126 substance Substances 0.000 claims description 34
- 238000004891 communication Methods 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 27
- 241000282414 Homo sapiens Species 0.000 claims description 23
- 210000000795 conjunctiva Anatomy 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 230000005670 electromagnetic radiation Effects 0.000 claims description 13
- 210000003491 skin Anatomy 0.000 claims description 13
- 238000004590 computer program Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000003925 fat Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000000835 fiber Substances 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 239000007857 degradation product Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000003722 extracellular fluid Anatomy 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 239000004973 liquid crystal related substance Substances 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000000845 cartilage Anatomy 0.000 claims description 3
- 210000003195 fascia Anatomy 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 claims description 3
- 210000003041 ligament Anatomy 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 210000002435 tendon Anatomy 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 3
- 235000001727 glucose Nutrition 0.000 claims 3
- 230000006855 networking Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 abstract description 19
- 238000006424 Flood reaction Methods 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 25
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 210000001742 aqueous humor Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 9
- 230000003595 spectral effect Effects 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 230000002596 correlated effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000005102 attenuated total reflection Methods 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 210000000744 eyelid Anatomy 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000003454 tympanic membrane Anatomy 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000624 ear auricle Anatomy 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910001120 nichrome Inorganic materials 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 230000005457 Black-body radiation Effects 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 231100000099 dermal / percutaneous penetration testing Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910018487 Ni—Cr Inorganic materials 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- HMDDXIMCDZRSNE-UHFFFAOYSA-N [C].[Si] Chemical compound [C].[Si] HMDDXIMCDZRSNE-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- VNNRSPGTAMTISX-UHFFFAOYSA-N chromium nickel Chemical compound [Cr].[Ni] VNNRSPGTAMTISX-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009615 fourier-transform spectroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 235000009643 reducing diet Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- PRZWBGYJMNFKBT-UHFFFAOYSA-N yttrium Chemical compound [Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y] PRZWBGYJMNFKBT-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Emergency Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La présente invention concerne des méthodes et des instruments non invasifs d'optique, permettant de détecter la présence ou de mesurer la concentration d'un grand nombre de substances à analyser, telles que le glucose, dans le tissu d'un sujet. Les spectres de rayonnement dans l'infrarouge moyen émis par le corps du sujet sont modifiés en fonction de la présence, de l'absence ou de la concentration de la substance à analyser dans le tissu du sujet. Dans un aspect de la présente invention, l'instrument balaye la surface du corps du sujet, tel que la peau ou l'oeil, tout orifice, conduit ou cavité, tel que la bouche, l'oreille ou le nez, avec une lumière dans l'infrarouge moyen, et détermine la présence, l'absence ou la concentration de la substance à analyser sur la base de la signature distincte du rayonnement dans l'infrarouge moyen de la substance à analyser renvoyé par réflexion vers l'instrument. Dans un autre aspect de l'invention, un instrument mesure le niveau du rayonnement dans l'infrarouge moyen à partir d'une surface du corps du sujet, y compris, sans en exclure d'autres, le rayonnement dans l'infrarouge moyen émis depuis une surface du corps, telle que la peau ou l'oeil, tout orifice, conduit ou cavité, tel que la bouche, l'oreille ou le nez, et détermine la présence, l'absence ou la concentration de la substance à analyser sur la base de la signature distincte du rayonnement dans l'infrarouge moyen de la substance à analyser. Dans un mode de réalisation préféré, la présente invention concerne des méthodes non invasives permettant de détecter la présence ou de mesurer la concentration d'un grand nombre de substances à analyser, telles que le glucose, dans la conjonctive d'un sujet. Les spectres du rayonnement dans l'infrarouge moyen émis ou renvoyés par réflexion par la conjonctive du sujet sont modifiés en fonction de la présence, de l'absence ou de la concentration de la substance à analyser dans la conjonctive du sujet. Dans un aspect de l'invention, la conjonctive de l'oeil du patient est utilisée comme une source d'un signal optique pour déterminer la présence, l'absence ou la concentration d'une substance à analyser sur la base des caractéristiques spectrales distinctes de la substance à analyser, détectées par un instrument capable de détecter le signal optique. Les mesures réalisées par l'instrument de la présente invention, sur la conjonctive ou toute autre partie du corps, ne nécessitent pas un contact direct de l'instrument avec une surface d'un corps du sujet.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006513353A JP2006525084A (ja) | 2003-05-02 | 2004-04-27 | 非侵襲的分析物測定のための方法およびデバイス |
| EP04760590A EP1622507A2 (fr) | 2003-05-02 | 2004-04-27 | Methodes et dispositifs permettant de mesurer une substance a analyser de facon non invasive |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46735503P | 2003-05-02 | 2003-05-02 | |
| US10/428,410 | 2003-05-02 | ||
| US10/428,410 US6968222B2 (en) | 2003-05-02 | 2003-05-02 | Methods and device for non-invasive analyte measurement |
| US60/467,355 | 2003-05-02 | ||
| US51339603P | 2003-10-21 | 2003-10-21 | |
| US60/513,396 | 2003-10-21 | ||
| US10/824,254 US6958039B2 (en) | 2003-05-02 | 2004-04-14 | Method and instruments for non-invasive analyte measurement |
| US10/824,214 | 2004-04-14 | ||
| US10/824,214 US6975892B2 (en) | 2003-10-21 | 2004-04-14 | Methods for non-invasive analyte measurement from the conjunctiva |
| US10/824,254 | 2004-04-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004099824A2 true WO2004099824A2 (fr) | 2004-11-18 |
| WO2004099824A3 WO2004099824A3 (fr) | 2005-01-20 |
Family
ID=33437252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/012893 WO2004099824A2 (fr) | 2003-05-02 | 2004-04-27 | Methodes et dispositifs permettant de mesurer une substance a analyser de façon non invasive |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1622507A2 (fr) |
| JP (1) | JP2006525084A (fr) |
| WO (1) | WO2004099824A2 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9442065B2 (en) | 2014-09-29 | 2016-09-13 | Zyomed Corp. | Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements |
| US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8044354B2 (en) * | 2008-12-04 | 2011-10-25 | The Boeing Company | Method for classifying resins types in carbon fiber reinforced plastic materials using IR spectroscopy |
| US10092208B2 (en) * | 2014-10-03 | 2018-10-09 | Advantest Corporation | Non-invasive in situ glucose level sensing using electromagnetic radiation |
| KR101981632B1 (ko) * | 2017-10-31 | 2019-05-24 | 주식회사 템퍼스 | 혈당 측정 장치 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020049389A1 (en) * | 1996-09-04 | 2002-04-25 | Abreu Marcio Marc | Noninvasive measurement of chemical substances |
| US6418332B1 (en) * | 1999-02-25 | 2002-07-09 | Minimed | Test plug and cable for a glucose monitor |
| US6424851B1 (en) * | 1998-10-13 | 2002-07-23 | Medoptix, Inc. | Infrared ATR glucose measurement system (II) |
| US20030018271A1 (en) * | 2001-07-02 | 2003-01-23 | Kimble Allan Wayne | Simplified and lightweight system for enhanced visualization of subcutaneous hemoglobin-containing structures |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1216409A1 (fr) * | 1999-09-17 | 2002-06-26 | Walter K. Proniewicz | Mesure non invasive du niveau de sucre dans le sang |
| ES2295344T3 (es) * | 2001-04-27 | 2008-04-16 | Eyesense Ag | Kit para medir concentraciones de glucosa en sangre. |
| US6836337B2 (en) * | 2001-09-20 | 2004-12-28 | Visual Pathways, Inc. | Non-invasive blood glucose monitoring by interferometry |
-
2004
- 2004-04-27 JP JP2006513353A patent/JP2006525084A/ja active Pending
- 2004-04-27 WO PCT/US2004/012893 patent/WO2004099824A2/fr active Application Filing
- 2004-04-27 EP EP04760590A patent/EP1622507A2/fr not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020049389A1 (en) * | 1996-09-04 | 2002-04-25 | Abreu Marcio Marc | Noninvasive measurement of chemical substances |
| US6424851B1 (en) * | 1998-10-13 | 2002-07-23 | Medoptix, Inc. | Infrared ATR glucose measurement system (II) |
| US6418332B1 (en) * | 1999-02-25 | 2002-07-09 | Minimed | Test plug and cable for a glucose monitor |
| US20030018271A1 (en) * | 2001-07-02 | 2003-01-23 | Kimble Allan Wayne | Simplified and lightweight system for enhanced visualization of subcutaneous hemoglobin-containing structures |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9442065B2 (en) | 2014-09-29 | 2016-09-13 | Zyomed Corp. | Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements |
| US9448164B2 (en) | 2014-09-29 | 2016-09-20 | Zyomed Corp. | Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing |
| US9448165B2 (en) | 2014-09-29 | 2016-09-20 | Zyomed Corp. | Systems and methods for control of illumination or radiation collection for blood glucose and other analyte detection and measurement using collision computing |
| US9453794B2 (en) | 2014-09-29 | 2016-09-27 | Zyomed Corp. | Systems and methods for blood glucose and other analyte detection and measurement using collision computing |
| US9459201B2 (en) | 2014-09-29 | 2016-10-04 | Zyomed Corp. | Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing |
| US9459202B2 (en) | 2014-09-29 | 2016-10-04 | Zyomed Corp. | Systems and methods for collision computing for detection and noninvasive measurement of blood glucose and other substances and events |
| US9459203B2 (en) | 2014-09-29 | 2016-10-04 | Zyomed, Corp. | Systems and methods for generating and using projector curve sets for universal calibration for noninvasive blood glucose and other measurements |
| US9610018B2 (en) | 2014-09-29 | 2017-04-04 | Zyomed Corp. | Systems and methods for measurement of heart rate and other heart-related characteristics from photoplethysmographic (PPG) signals using collision computing |
| US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006525084A (ja) | 2006-11-09 |
| EP1622507A2 (fr) | 2006-02-08 |
| WO2004099824A3 (fr) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6968222B2 (en) | Methods and device for non-invasive analyte measurement | |
| US6958039B2 (en) | Method and instruments for non-invasive analyte measurement | |
| US6975892B2 (en) | Methods for non-invasive analyte measurement from the conjunctiva | |
| Do Amaral et al. | Current development in non-invasive glucose monitoring | |
| US20060258918A1 (en) | Combination Analyte Measurement Device and Method of Use | |
| US6430424B1 (en) | Infrared ATR glucose measurement system utilizing a single surface of skin | |
| US20060224057A1 (en) | Methods for non-invasive analyte measurement | |
| US6442410B1 (en) | Non-invasive blood glucose measurement system and method using optical refractometry | |
| EP0828533B1 (fr) | Procede et appareil permettant l'evaluation rapide et non invasive des parametres de la composition sanguine | |
| US20020026106A1 (en) | Non-invasive sensor having controllable temperature feature | |
| US20060258920A1 (en) | Non-Invasive Analyte Measurement Glasses and Method of Use | |
| WO2006079797A2 (fr) | Dispositif permettant de mesurer la concentration d'un melange a analyser | |
| Losoya-Leal et al. | State of the art and new perspectives in non-invasive glucose sensors | |
| US9026188B2 (en) | Measurement apparatus and method therefor | |
| GB2482378A (en) | Determining analyte concentration using optical assembly interference pattern | |
| EP1622507A2 (fr) | Methodes et dispositifs permettant de mesurer une substance a analyser de facon non invasive | |
| US20080009688A1 (en) | Methods for non-invasive analyte measurement | |
| Mohanram et al. | Measurement of blood glucose using non-invasive methods–a review | |
| US20090240124A1 (en) | Systems and Methods for Measuring the Concentration of Analytes in the Human Eye | |
| US20060258919A1 (en) | Non-Invasive Analyte Measurement Device for Measuring Tears and Other Ocular Elements Using Electromagnetic Radiation and Method of Using the Same | |
| Talukdar | Non-Invasive Measurement of Glucose Content in Human Body: A Comparative Study | |
| Khan et al. | Non-Invasive Blood Glucose Measurement Device: Performance analysis of Diffused Reflectance method and Diffused Transmittance method using Near Infrared Light | |
| Ben-David et al. | Noninvasive glucose monitoring | |
| MXPA01003773A (en) | Infrared atr glucose measurement system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2004760590 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006513353 Country of ref document: JP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004760590 Country of ref document: EP |